Revance Inc.

Industry

  • Digital Health
    • Disease Management
  • Pharmaceuticals
    • Nutraceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Contract Research Organization-CRO

Other Names/Subsidiaries

  • Crown Laboratories
  • Del-Ray Dermatologicals
  • Med-Derm Pharmaceuticals
  • Revance Therapeutics
See more in Biomedtracker

Latest on Revance Inc.

Scrip

M&A Took A Holiday In Q3, With Decreased Volume And Value

 
• By Joseph Haas

Merger-and-acquisition activity in the biopharmaceutical sector fell off sharply during the third quarter, a second consecutive quarter of decline after the busy and high-spending Q4 2023 and Q1 2024,

Scrip

Deal Watch: Revance To Go Private In Crown Laboratories Buyout

 
• By Joseph Haas and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Crown Will Offer $924m To Merge With Re

HBW Insight

GSK Offloads Physiogel In North America, Asia To Korea’s LG

 
• By Tom Gallen

South Korea’s [LG Household & Health Care Ltd.] – a subsidiary of the multinational conglomerate LG Corporation – has acquired from GlaxoSmithKline PLC the rights to the Physiogel skin-care brand in

HBW Insight

GSK Plans Further Divestments As Pfizer Brands Drive Up Q3 Sales

 
• By Tom Gallen

GlaxoSmithKline PLC portfolio rationalization efforts, which has seen it shed mainly skin-care and nutrition assets over the past 12 months, will continue into 2020 as the firm looks to generate the